Cambria Pharmaceuticals Reaps $5.4M Financing

Erik Mellgren4/22/08

Cambria Pharmaceuticals of Woburn, MA, has received $5.4 in a Series A round joined by Biogen Idec New Ventures, CommonAngels, and several individual investors, the company announced today. Cambria aims to find new treatments for neurological disorders, especially ALS, also known as Lou Gehrig’s disease.

Erik Mellgren is a Swedish journalist who worked for Xconomy Boston in 2008 as part of the Stanford Innovation Journalism Fellowship program. His real job is with Ny Teknik, a leading technology and innovation magazine in Sweden, but he loved seeing the Red Sox at Fenway.